Investors

MediPharm Labs is an international leader in the production and manufacturing of purified, pharmaceutical-quality cannabis extracts and goods.

We are committed to driving value for our investors by leveraging our credentials to continue to support the growing need for cannabinoid based API, globally.

Download the latest Presentation

Management and Board of Directors

Lorem ipsum dolor sit amet. Ut quam ipsa At dolore voluptatem aut voluptate laborum id aliquid ipsam ut fugiat quisquam. Qui quam galisum quo mollitia cumque nam voluptas saepe sit Quis soluta non corporis voluptatem et molestiae sint. Est consequatur corporis aut molestias similique hic Quis consequatur in quia autem rem soluta architecto qui modi sunt!

Chris Taves
Chairman of the board

Chris Taves was appointed Chief Operating Officer, BMO Capital Markets in January 2018. In this role, he has oversight of all balance sheet and risk taking activity, as well as regulatory, compliance, and operational functions to ensure they are optimized to satisfy client needs and BMO FG requirements.

Mr. Taves brings over 20 years of customer facing experience covering corporate and institutional clients across a wide range of products, including derivatives, investments, and corporate finance, working closely with I&CB and all areas within Trading Products. Since joining BMO in 2009, he has taken on broader mandates within the Trading Products team, most recently as Co-Head of Global Trading Products.

Mr. Taves is part of the BMO Capital Markets Operating and Executive Committees, the board of BMO Capital Market’s US broker-dealer – BMO Capital Markets Corp., the board of BMO China, and various other leadership committees within BMO Capital Markets and BMO Financial Group.

Mr. Taves holds an MBA from the Ivey School of Business at the University of Western Ontario, a Mathematics degree from the University of Waterloo, and is a Chartered Professional Accountant. He is a member of the United Way Toronto and York Region Major Individual Giving Cabinet and a Director on the board of Armagh, a second-stage housing program for abused women, Operating and Executive committees.

David Pidduck
Chief Executive Officer

David Pidduck joined MediPharm Labs with over 20 years experience in the Canadian and international pharmaceutical industries. David has a wealth of experience in driving strategic change in complex and ambiguous environments. His previous roles within the pharmaceutical industry have centred around transformation, portfolio and channel diversification, and he’s been recognized for driving significant revenue and profit growth during his tenures. David prides himself in being a people-centric leader who has been able to increase employee engagement while transforming multi-national organizations.

David holds an EMBA from the Kellogg School of Business at Northwestern University, and an Honors BBA from Wilfred Laurier University.

Shelley Potts
Independent Director

Shelley is the former President and CEO of Nestlé Canada and a consumer packaged goods industry top executive with an outstanding track record of success. Ms. Martin served in a variety of senior executive roles at Nestlé Canada Inc. from 1990 until she retired after five years as President and Chief Executive Officer in 2018. During her time leading Nestlé Canada, she drove a substantial increase in revenue, market share and profitability and transformed core business units and brands by introducing new formulas, packaging, pricing, global sources of supply and Lean (Six Sigma) tools. In 2018, Nestlé Canada’s annual sales were approximately $2.6 billion. She began her career at General Mills Canada in 1985 and was named one of Canada’s Most Powerful Women by the Women’s Executive Network (WXN) in 2015, 2016 and 2018. Ms. Martin is a member of the Advisory Board of Moosehead Breweries as well as Crosby Molasses, and is a Director of Vineland Research and Innovation Centre, a leader in horticultural research and innovation. From 2016 to 2018, she served as Board Chair of Food & Consumer Products of Canada (FCPC), which represents more than 100 food, beverage, and consumer product manufacturers of all sizes. From 2013 to 2018, she was a Director of The Grocery Foundation, a not-for-profit organization that has raised over $90 million for student nutrition programs. Ms. Martin is a graduate of Wilfrid Laurier University (Bachelor of Business Administration) and earned the Institute of Corporate Directors ICD. D designation in 2016.

Chris Halyk
Independent Director

Mr. Halyk has 35 years of pharmaceutical industry experience including 33 years with Johnson & Johnson. Among his many career highlights, he served as: Vice-President, Sales and Marketing and a member of the Janssen Management Board with responsibility for innovations in direct-to-consumer advertising, patient education and sales force automation; Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc.; and from 2006 until his retirement in 2019 as the President of Janssen Inc. (Canada) where under his leadership, the company became the largest pharmaceutical company in Canada. During his tenure, his accomplishments included, bringing innovative products, services and solutions to market along with new technologies and treatments in oncology, immunology, neuroscience, infectious diseases and vaccines, cardiovascular and metabolism and pulmonary hypertension. Mr. Halyk holds an Honours Business Administration degree from Ivey Business School at Western University. He served as the Chair of the Board of Directors for Rx&D, the industry association for Canada’s Research-Based Pharmaceutical Companies (now named Innovative Medicines Canada) from 2012 until 2013. Before joining Johnson & Johnson, Mr. Halyk worked for pharmaceutical company Warner-Lambert in Toronto.

Miriam McDonald
Independent Director

Miriam is currently the Director of Pharmacy at Health Sciences North, Northern Ontario’s largest hospital located in Sudbury. She holds a Bachelor of Science in Pharmacy from the University of Toronto and a Master of Science in Pharmacology from Queens University. Her career has encompassed positions as the Executive Director of Community Development at the Northern Ontario School of Medicine, and CEO of the Northeastern Ontario Medical Education Corporation (NOMEC) wherein she worked throughout northern Ontario to facilitate community-based medical clinical education. She also served as Director of Planning and Development of Cambrian College, Executive Director of Cambrian Foundation, and Director of Pharmacy, Director of Rehabilitation Services and Assistant Executive Director of Therapeutic Services at Laurentian Hospital. She was Project Coordinator for the planning and construction of the Glenn Crombie Special Needs Centre, the Northern Centre for Advanced Technology (NORCAT), and the Northeastern Cancer Centre. She is the author and co-author of several health-related papers and studies and is very active in the community both on a personal and professional level. She has been recognized by Northern Ontario Business as a “Woman of Influence”, was the recipient of the Sudbury Business and Professional Women’s Club highest honor – the Bernardine Yackman Award, and has served on the Women’s Health Council of Ontario and Ontario Judicial Appointment Advisory Committee. Raised in northern Ontario, her strongest interest is in projects that address access to health, education, and information technology in northern Ontario.

Dr. Paul Tam, MBBS, FRCP(C), FACP
Independent Director

With more than three decades of clinical research and medical practice experience, Dr. Paul Tam is a globally recognized expert in the field of nephrology and a pioneer in the development of continuous renal replacement therapy for acute kidney injury.  In 1996, Dr. Tam founded the Scarborough Regional Nephrology Program where he is currently Medical Director of the largest community nephrology program in Canada. Dr. Tam oversees a team of thirteen nephrologists that provide renal care to over 900 dialysis patients and 4,000 chronic kidney disease patients and is also an active staff nephrologist at The Scarborough Hospital. Dr. Tam is also the Medical Quality Advisor for three major Independent Health Facilities that provide hemodialysis care. Dr. Tam has extensive and highly specialized experience in pharmaceutical development having co-founded and acted as the Medical Director overseeing operations and clinical research for a contract research organization which was ultimately acquired by the Biovail Corporation. Dr. Tam served as a Director of Biovail Corporation after the acquisition and he also served as the Medical Director of Contract Research arm of Biovail Corporation. Dr. Tam continues to be active in clinical research and participate in multi-national trials, product commercialization and is a highly respected subject matter author. Dr. Tam also leads and serves on multiple professional and executive governance committees.  He is an active member and past Section Chair representing the Nephrology Specialty of the Ontario Medical Association, and active member and past Chair of the Ontario Association of Nephrologists.  In the past he has also served on the Boards of Directors for pharmaceutical companies. Dr. Tam received his medical degree from The University of Hong Kong and completed further specialization at the University of Toronto, Canada.

Stock Data

Stock Quote

Medipharm Labs Corp
Toronto Stock Exchange: LABS:CA

Detailed Information

Today
Current Date
Last
Price
% Chg
Price
High
Price
Volume
Quantity
Open
Price
Low
Price
Change
Price
Prev. Close
Price
Share Information
Year High
Price
Shares Out
Price
VWAP
Price
Year Low
Price
Market Cap
Price
Exchange
TSX
PB Ratio
ratio

Stock Quote

Medipharm Labs Corp
OTCQX Marketplace: MEDIF

Detailed Information

Today
Current Date
Last
Price
% Chg
Price
High
Price
Volume
Quantity
Open
Price
Low
Price
Change
Price
Prev. Close
Price
Share Information
Year High
Price
Shares Out
Price
VWAP
Price
Year Low
Price
Market Cap
Price
Exchange
OTCQX
PB Ratio
ratio

Stock Quote

Medipharm Labs Corp
Berlin: MLZ:BE

Detailed Information

Today
Current Date
Last
Price
% Chg
Price
High
Price
Volume
Quantity
Open
Price
Low
Price
Change
Price
Prev. Close
Price
Share Information
Year High
Price
Shares Out
Price
VWAP
Price
Year Low
Price
Market Cap
Price
Exchange
BE
PB Ratio
ratio

Firm

Analysts

Email

AltaCorp Capital
David Kideckel
DKideckel@altacorpcapital.com
Canaccord Genuity
Matthew Bottomly
mbottomley@cgf.com
Mackie Research Capital Corporation
Greg McLeish
gmcleish@mackieresearch.com
Roth Capital Partners
Scott Fortune
sfortune@roth.com
Scotia Capital Inc.
Adam Buckham
adam.buckham@scotiabank.com

All analyst coverage is conducted by third parties. Please note that any opinions, estimates or forecasts regarding MediPharm Labs' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of MediPharm Labs or its management. MediPharm Labs does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. As such the content of any analyst coverage should not be considered financial advice or forecasting that is approved or endorsed by MediPharm Labs.

Sedar

MediPharm Labs Corp.
Learn More

Financial results

Q1

2022

Quarter Ended Mar 31, 2022
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2022

FY

2021

Fiscal Year Ended Dec 31,2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

Q3

2021

Quarter Ended Sep 30, 2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

Q2

2021

Quarter Ended Jun 30, 2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

Q1

2021

Quarter Ended Mar 31, 2021
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2021

FY

2020

Fiscal Year Ended Dec 31, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

Q3

2020

Quarter Ended Sep 30, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

Q2

2020

Quarter Ended Jun 30, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

Q1

2020

Quarter Ended Mar 31, 2020
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2020

FY

2019

Fiscal Year Ended Dec 31, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

Q3

2019

Quarter Ended Sep 30, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

Q2

2019

Quarter Ended Jun 30, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

Q1

2019

Quarter Ended Mar 31, 2019
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2019

FY

2018

Fiscal Year Ended Dec 31, 2018
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2018

Q3

2018

Quarter Ended Sep 30, 2018
Earnings Release
Earnings Webcast
Conference Call Presentation
Financial Statements
MD&A
AIF
Annual Report
2018
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Corporate Governance

Governance Statement

The Board of Directors of MediPharm Labs Corp. (the “Company”) sets high standards for the Company’s service providers, employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Governance at a Glance
Chair
Member
Board Member
Audit
Compensation
Corporate Governance
and Nomination
Science
Chris taves
David Pidduck
Chris Halyk
Shelley Martin
Miriam McDonald
Dr. Paul Tam
Board Committees
Chair
Member
Audit Committee
Position
Chris taves
Shelley Martin
Miriam McDonald
Audit Committee Charter
Compensation Committee
Position
Chris HALYK
Shelley Martin
DR. paul tam
Compensation Committee Charter
Corporate Governance and Nomination Committee
Position
Chris halyk
Shelley Martin
dr. paul tam
Corporate Governance and Nomination Committee Charter
Science Committee
Position
Chris taves
Shelley Martin
Miriam McDonald